

**Clinical trial results:****A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects with Chronic Hepatitis C Virus Related Thrombocytopenia who are Potential Candidates for Antiviral Treatment****Summary**

EudraCT number	2010-024479-20
Trial protocol	DE BG
Global end of trial date	01 May 2014

**Results information**

Result version number	v2 (current)
This version publication date	25 March 2016
First version publication date	05 August 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Results are being revised due to training issue with our staff and to reconcile the results to ensure consistency with ClinicalTrials.gov results.

**Trial information****Trial identification**

Sponsor protocol code	E5501-G000-203
-----------------------	----------------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01355289
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Eisai
Sponsor organisation address	155 Tice Boulevard, Woodcliff Lake, United States, 07677
Public contact	Medical Information, Eisai Limited, +44 08456761400, LmedInfo@eisai.net
Scientific contact	Medical Information, Eisai Limited, +44 08456761400, LmedInfo@eisai.net

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 May 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 May 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment

Protection of trial subjects:

This study was conducted in accordance with standard operating procedures (SOPs) of the sponsor (or designee), which are designed to ensure adherence to Good Clinical Practice (GCP) guidelines as required by the following:

- Principles of the World Medical Association Declaration of Helsinki (World Medical Association, 2008)
- International Conference on Harmonisation (ICH) E6 Guideline for GCP (CPMP/ICH/135/95) of the European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, International Conference on Harmonisation of Pharmaceuticals for Human Use
- Title 21 of the United States (US) Code of Federal Regulations (US 21 CFR) regarding clinical studies, including Part 50 and Part 56 concerning informed subject consent and Institutional Review Board (IRB) regulations and applicable sections of US 21 CFR Part 312
- European Good Clinical Practice Directive 2005/28/EC and Clinical Trial Directive 2001/20/EC for studies conducted within any European Union (EU) country. All suspected unexpected serious adverse reactions were reported, as required, to the Competent Authorities of all involved EU member states.
- Article 14, Paragraph 3, and Article 80-2 of the Pharmaceutical Affairs Law (Law No. 145, 1960) for studies conducted in Japan, in addition to Japan's GCP Subject Information and Informed Consent.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 3
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Israel: 9
Country: Number of subjects enrolled	United States: 45

Worldwide total number of subjects	65
EEA total number of subjects	11

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	60
From 65 to 84 years	5
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The Screening Period encompassed 14 days  $\pm$ 7 days. Prerandomization assessments took place in all participants who had provided informed consent.

### Period 1

Period 1 title	Core Study
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo (Core Study)

Arm description:

Placebo, was administered orally, once daily for up to 21 days.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Once daily.

<b>Arm title</b>	Avatrombopag 10 mg (Core Study)
------------------	---------------------------------

Arm description:

Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.

Arm type	Active comparator
Investigational medicinal product name	Avatrombopag
Investigational medicinal product code	E5501
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

10 mg, tablet form, orally, once daily.

<b>Arm title</b>	Avatrombopag 20 mg (Core Study)
------------------	---------------------------------

Arm description:

Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.

Arm type	Active comparator
Investigational medicinal product name	Avatrombopag
Investigational medicinal product code	E5501
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:  
20 mg, tablet form, orally, once daily.

<b>Arm title</b>	Avatrombopag 30 mg (Core Study)
Arm description: Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.	
Arm type	Active comparator
Investigational medicinal product name	Avatrombopag
Investigational medicinal product code	E5501
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:  
30 mg, tablet form, orally, once daily.

<b>Number of subjects in period 1</b>	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)	Avatrombopag 20 mg (Core Study)
Started	17	16	18
Completed	16	16	18
Not completed	1	0	0
Adverse event, non-fatal	1	-	-
Not specified	-	-	-
Inadequate therapeutic effect	-	-	-

<b>Number of subjects in period 1</b>	Avatrombopag 30 mg (Core Study)
Started	14
Completed	12
Not completed	2
Adverse event, non-fatal	-
Not specified	1
Inadequate therapeutic effect	1

## Period 2

Period 2 title	Open Label Extension (OLE)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

---

**Arms**

<b>Arm title</b>	Avatrombopag (Open Label Extension)
------------------	-------------------------------------

---

Arm description:

Avatrombopag was initiated at a dose of 20 mg, once daily in the open label extension (OLE) period. The avatrombopag dose was titrated up or down in accordance with their individual response within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.

Arm type	Experimental
----------	--------------

---

Investigational medicinal product name	Avatrombopag
--	--------------

---

Investigational medicinal product code	E5501
--	-------

---

Other name	
------------	--

---

Pharmaceutical forms	Tablet
----------------------	--------

---

Routes of administration	Oral use
--------------------------	----------

---

Dosage and administration details:

5-50 mg, tablet form, orally, once daily.

<b>Number of subjects in period 2</b>	Avatrombopag (Open Label Extension)
Started	62
Completed	28
Not completed	34
Adverse event, non-fatal	1
Not specified	3
Lost to follow-up	1
Lack of efficacy	29

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo (Core Study)
Reporting group description: Placebo, was administered orally, once daily for up to 21 days.	
Reporting group title	Avatrombopag 10 mg (Core Study)
Reporting group description: Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.	
Reporting group title	Avatrombopag 20 mg (Core Study)
Reporting group description: Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.	
Reporting group title	Avatrombopag 30 mg (Core Study)
Reporting group description: Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.	

Reporting group values	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)	Avatrombopag 20 mg (Core Study)
Number of subjects	17	16	18
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	50.2	55.3	54.9
standard deviation	± 7.96	± 8.06	± 7.38
Gender categorical Units: Subjects			
Female	3	4	5
Male	14	12	13

Reporting group values	Avatrombopag 30 mg (Core Study)	Total	
Number of subjects	14	65	
Age categorical Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	

Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	53.6		
standard deviation	± 7.26	-	
Gender categorical			
Units: Subjects			
Female	5	17	
Male	9	48	

## End points

### End points reporting groups

Reporting group title	Placebo (Core Study)
Reporting group description: Placebo, was administered orally, once daily for up to 21 days.	
Reporting group title	Avatrombopag 10 mg (Core Study)
Reporting group description: Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.	
Reporting group title	Avatrombopag 20 mg (Core Study)
Reporting group description: Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.	
Reporting group title	Avatrombopag 30 mg (Core Study)
Reporting group description: Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.	
Reporting group title	Avatrombopag (Open Label Extension)
Reporting group description: Avatrombopag was initiated at a dose of 20 mg, once daily in the open label extension (OLE) period. The avatrombopag dose was titrated up or down in accordance with their individual response within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.	
Subject analysis set title	Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description: The full analysis set was the group of randomized participants.	

### Primary: Number of participants who achieved Platelet Response (greater than or equal to $100 \times 10^9/L$ ) by Day 21 of Treatment Period A1 of Core Study

End point title	Number of participants who achieved Platelet Response (greater than or equal to $100 \times 10^9/L$ ) by Day 21 of Treatment Period A1 of Core Study			
End point description: A responder was defined as a participant having a platelet count of greater than or equal to $100 \times 10^9/L$ by Day 21 starting from an average baseline platelet count of greater than $20 \times 10^9/L$ to less than or equal to $70 \times 10^9/L$ .				
End point type	Primary			
End point timeframe: Baseline to Day 21				

End point values	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)	Avatrombopag 20 mg (Core Study)	Avatrombopag 30 mg (Core Study)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	16	18	14
Units: Participants				
number (not applicable)				
Yes	1	6	12	9
No	16	10	6	5

## Statistical analyses

<b>Statistical analysis title</b>	Difference of response rate (10 mg) vs placebo
Comparison groups	Avatrombopag 10 mg (Core Study) v Placebo (Core Study)
Number of subjects included in analysis	33
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0236
Method	Cochran-Mantel-Haenszel
Parameter estimate	Median difference (final values)
Point estimate	31.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.39
upper limit	57.84

<b>Statistical analysis title</b>	Difference of response rate (20 mg) vs placebo
Comparison groups	Placebo (Core Study) v Avatrombopag 20 mg (Core Study)
Number of subjects included in analysis	35
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Cochran-Mantel-Haenszel
Parameter estimate	Median difference (final values)
Point estimate	60.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	36.3
upper limit	85.27

<b>Statistical analysis title</b>	Difference of response rate (30 mg) vs placebo
Comparison groups	Placebo (Core Study) v Avatrombopag 30 mg (Core Study)

Number of subjects included in analysis	31
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Cochran-Mantel-Haenszel
Parameter estimate	Median difference (final values)
Point estimate	58.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	30.92
upper limit	85.88

### Secondary: Change from Baseline of Local Platelet Count by Visit during Treatment Period A1 of Core Study

End point title	Change from Baseline of Local Platelet Count by Visit during Treatment Period A1 of Core Study
End point description: Missing platelet counts were imputed using last observation carried forward (LOCF) approach for subjects who achieved platelet response at prior visits.	
End point type	Secondary
End point timeframe: Day 7 and Day 14	

End point values	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)	Avatrombopag 20 mg (Core Study)	Avatrombopag 30 mg (Core Study)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	16	18	14
Units: x10 <sup>9</sup> /L				
arithmetic mean (standard deviation)				
Day 7	-0.1 (± 7.15)	19.8 (± 17.59)	26.5 (± 22.06)	30.9 (± 37.65)
Day 14	-0.2 (± 13.79)	29.2 (± 18.32)	57.2 (± 31.39)	55.4 (± 37.47)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants who achieved Platelet Count greater than 30 X 10<sup>9</sup>/L from Baseline to Day 21 during Treatment Period A1 of Core Study

End point title	Number of Participants who achieved Platelet Count greater than 30 X 10 <sup>9</sup> /L from Baseline to Day 21 during Treatment Period A1 of Core Study
End point description: Blood draws were taken to monitor platelet counts.	
End point type	Secondary

End point timeframe:

Baseline to Day 21

<b>End point values</b>	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)	Avatrombopag 20 mg (Core Study)	Avatrombopag 30 mg (Core Study)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	16	18	14
Units: Participants				
number (not applicable)				
Yes	1	9	16	11
No	16	7	2	3

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study

End point title	Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study
End point description:	Blood draws were taken to monitor platelet counts during the first 21 days of study treatment. When a platelet count of greater than or equal to $100 \times 10^9/L$ was attained, antiviral treatment was initiated.
End point type	Secondary
End point timeframe:	Baseline to Day 21

<b>End point values</b>	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)	Avatrombopag 20 mg (Core Study)	Avatrombopag 30 mg (Core Study)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	17	16	18	14
Units: Participants				
number (not applicable)				
Yes	1	6	13	9
No	16	10	5	5

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

For each participant, treatment emergent adverse events were collected from the first day of administration of study drug up to 30 days after the last dose of study drug or up to approximately 2.5 years.

Adverse event reporting additional description:

Safety Analysis Set was used which combines data of the Core and Extension Phase and includes subjects who had at least 1 dose of avatrombopag. Placebo treatment arm was excluded since not part of study design for the Extension Phase.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.0
--------------------	------

### Reporting groups

Reporting group title	Avatrombopag (Open Label Extension)
-----------------------	-------------------------------------

Reporting group description:

During the core study, participants were administered a fixed dose of Avatrombopag 10mg, 20mg, or 30mg, orally, once daily, preferably with food for upto 21 days. The participants initiated Open label extension with Avontrambopag 20 mg, once daily. The avotrambopag dose was titrated up or down in accordance with their individual response, within the range of a minimum of 5mg and a maximum of 50 mg for up to 48 weeks.

Reporting group title	Placebo (Core Study)
-----------------------	----------------------

Reporting group description:

Placebo, was given orally for up to 21 days once daily.

Reporting group title	Avatrombopag 10 mg (Core Study)
-----------------------	---------------------------------

Reporting group description:

Avatrombopag 10 mg, was administered orally, once daily, preferably with food for up to 21 days.

Reporting group title	Avatrombopag 20 mg (Core Study)
-----------------------	---------------------------------

Reporting group description:

Avatrombopag 20 mg, was administered orally, once daily, preferably with food for up to 21 days.

Reporting group title	Avatrombopag 30 mg (Core Study)
-----------------------	---------------------------------

Reporting group description:

Avatrombopag 30 mg, was administered orally, once daily, preferably with food for up to 21 days.

<b>Serious adverse events</b>	Avatrombopag (Open Label Extension)	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 64 (20.31%)	0 / 17 (0.00%)	1 / 16 (6.25%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Nervous system disorders			
Paraesthesia			

subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	2 / 64 (3.13%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Leukopenia</b>			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			
subjects affected / exposed	2 / 64 (3.13%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancytopenia</b>			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombocytopenia</b>			
subjects affected / exposed	2 / 64 (3.13%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
<b>Hepatic mass</b>			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure acute			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperuricaemia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Avatrombopag 20 mg (Core Study)	Avatrombopag 30 mg (Core Study)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Nervous system disorders			
Paraesthesia			

subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Leukopenia</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Neutropenia</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pancytopenia</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Thrombocytopenia</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
<b>Hepatic mass</b>			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure acute			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperuricaemia			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Avatrombopag (Open Label Extension)	Placebo (Core Study)	Avatrombopag 10 mg (Core Study)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	55 / 64 (85.94%)	6 / 17 (35.29%)	11 / 16 (68.75%)
Vascular disorders			

Hot flush			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Pallor			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	8 / 64 (12.50%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	9	0	2
Chills			
subjects affected / exposed	13 / 64 (20.31%)	1 / 17 (5.88%)	3 / 16 (18.75%)
occurrences (all)	14	1	3
Fatigue			
subjects affected / exposed	16 / 64 (25.00%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	17	0	1
Influenza like illness			
subjects affected / exposed	11 / 64 (17.19%)	2 / 17 (11.76%)	1 / 16 (6.25%)
occurrences (all)	13	2	1
Injection site erythema			
subjects affected / exposed	6 / 64 (9.38%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	7	0	1
Irritability			
subjects affected / exposed	7 / 64 (10.94%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	7	0	0
Oedema peripheral			
subjects affected / exposed	6 / 64 (9.38%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0
Pyrexia			
subjects affected / exposed	9 / 64 (14.06%)	1 / 17 (5.88%)	0 / 16 (0.00%)
occurrences (all)	13	1	0
Chest discomfort			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Feeling cold			

subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Feeling of body temperature change			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Injection site pruritus			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Spontaneous penile erection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	9 / 64 (14.06%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	10	0	0
Dyspnoea			
subjects affected / exposed	4 / 64 (6.25%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	4	0	0
Dyspnoea exertional			
subjects affected / exposed	4 / 64 (6.25%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	5	0	1
Epistaxis			
subjects affected / exposed	6 / 64 (9.38%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	7	0	1
Productive cough			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			

subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Psychiatric disorders			
Depression			
subjects affected / exposed occurrences (all)	5 / 64 (7.81%) 6	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Insomnia			
subjects affected / exposed occurrences (all)	13 / 64 (20.31%) 13	1 / 17 (5.88%) 1	1 / 16 (6.25%) 1
Anxiety			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 17 (5.88%) 1	1 / 16 (6.25%) 1
Food aversion			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	1 / 16 (6.25%) 0
Mood altered			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Sleep disorder			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	1 / 16 (6.25%) 1
Investigations			
Staphylococcus test positive			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Weight decreased			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 17 (5.88%) 1	0 / 16 (0.00%) 0
Injury, poisoning and procedural complications			
Burns first degree			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	1 / 16 (6.25%) 1
Tooth fracture			
subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Congenital, familial and genetic disorders			

Congenital lymphoedema subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	1 / 16 (6.25%) 1
Cardiac disorders			
Palpitations subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 17 (5.88%) 1	0 / 16 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	4 / 64 (6.25%) 4	1 / 17 (5.88%) 1	0 / 16 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	12 / 64 (18.75%) 16	1 / 17 (5.88%) 1	0 / 16 (0.00%) 0
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	1 / 16 (6.25%) 1
Dysgeusia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Hypoaesthesia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Mental impairment subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Syncope			

subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	21 / 64 (32.81%)	0 / 17 (0.00%)	2 / 16 (12.50%)
occurrences (all)	26	0	3
<b>Leukopenia</b>			
subjects affected / exposed	14 / 64 (21.88%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	14	0	2
<b>Lymphopenia</b>			
subjects affected / exposed	5 / 64 (7.81%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0
<b>Neutropenia</b>			
subjects affected / exposed	20 / 64 (31.25%)	0 / 17 (0.00%)	2 / 16 (12.50%)
occurrences (all)	24	0	2
<b>Ear and labyrinth disorders</b>			
<b>Vertigo</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	6 / 64 (9.38%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0
<b>Abdominal pain upper</b>			
subjects affected / exposed	5 / 64 (7.81%)	1 / 17 (5.88%)	1 / 16 (6.25%)
occurrences (all)	5	1	1
<b>Ascites</b>			
subjects affected / exposed	6 / 64 (9.38%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0
<b>Diarrhoea</b>			
subjects affected / exposed	11 / 64 (17.19%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	12	0	1
<b>Dyspepsia</b>			
subjects affected / exposed	4 / 64 (6.25%)	0 / 17 (0.00%)	2 / 16 (12.50%)
occurrences (all)	4	0	2
<b>Haemorrhoids</b>			

subjects affected / exposed	4 / 64 (6.25%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0
Nausea			
subjects affected / exposed	20 / 64 (31.25%)	0 / 17 (0.00%)	3 / 16 (18.75%)
occurrences (all)	22	0	3
Vomiting			
subjects affected / exposed	8 / 64 (12.50%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	10	0	0
Abdominal distension			
subjects affected / exposed	0 / 64 (0.00%)	1 / 17 (5.88%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Anal pruritus			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Aphthous stomatitis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 17 (5.88%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 64 (0.00%)	1 / 17 (5.88%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Flatulence			
subjects affected / exposed	0 / 64 (0.00%)	1 / 17 (5.88%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Proctalgia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Liver tenderness			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	15 / 64 (23.44%)	0 / 17 (0.00%)	4 / 16 (25.00%)
occurrences (all)	15	0	4
Rash			

subjects affected / exposed occurrences (all)	12 / 64 (18.75%) 14	2 / 17 (11.76%) 2	1 / 16 (6.25%) 1
Rash macular subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	1 / 16 (6.25%) 1
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Muscle tightness subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 17 (5.88%) 1	0 / 16 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	4 / 64 (6.25%) 4	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	4 / 64 (6.25%) 5	0 / 17 (0.00%) 0	2 / 16 (12.50%) 2
Abscess limb subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Cellulitis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 17 (0.00%) 0	0 / 16 (0.00%) 0
Metabolism and nutrition disorders			

Hyperuricaemia			
subjects affected / exposed	4 / 64 (6.25%)	1 / 17 (5.88%)	0 / 16 (0.00%)
occurrences (all)	5	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 17 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 17 (5.88%)	0 / 16 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	Avatrombopag 20 mg (Core Study)	Avatrombopag 30 mg (Core Study)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 18 (66.67%)	11 / 14 (78.57%)	
Vascular disorders			
Hot flush			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences (all)	0	0	
Pallor			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 18 (11.11%)	1 / 14 (7.14%)	
occurrences (all)	2	1	
Chills			
subjects affected / exposed	3 / 18 (16.67%)	1 / 14 (7.14%)	
occurrences (all)	3	2	
Fatigue			
subjects affected / exposed	3 / 18 (16.67%)	2 / 14 (14.29%)	
occurrences (all)	4	2	
Influenza like illness			
subjects affected / exposed	4 / 18 (22.22%)	3 / 14 (21.43%)	
occurrences (all)	4	3	
Injection site erythema			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	

Irritability			
subjects affected / exposed	1 / 18 (5.56%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Oedema peripheral			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	2 / 18 (11.11%)	2 / 14 (14.29%)	
occurrences (all)	2	2	
Chest discomfort			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences (all)	0	0	
Feeling cold			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
Feeling of body temperature change			
subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)	
occurrences (all)	0	1	
Injection site pruritus			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
Pain			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders			
Spontaneous penile erection			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 18 (11.11%)	3 / 14 (21.43%)	
occurrences (all)	2	3	
Dyspnoea			
subjects affected / exposed	2 / 18 (11.11%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Dyspnoea exertional			

subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 14 (7.14%) 1	
Epistaxis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	2 / 14 (14.29%) 2	
Productive cough subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 14 (7.14%) 1	
Respiratory tract congestion subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 14 (0.00%) 0	
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Insomnia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	3 / 14 (21.43%) 3	
Anxiety subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 14 (7.14%) 1	
Food aversion subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Mood altered subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 2	
Sleep disorder subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Investigations			
Staphylococcus test positive			

subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 14 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Injury, poisoning and procedural complications Burns first degree subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Tooth fracture subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Congenital, familial and genetic disorders Congenital lymphoedema subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Tachycardia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Headache subjects affected / exposed occurrences (all)	3 / 18 (16.67%) 3	2 / 14 (14.29%) 3	
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Dysgeusia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	

Hypoaesthesia			
subjects affected / exposed	1 / 18 (5.56%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Mental impairment			
subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)	
occurrences (all)	0	1	
Sciatica			
subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)	
occurrences (all)	0	1	
Somnolence			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
Syncope			
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 18 (11.11%)	1 / 14 (7.14%)	
occurrences (all)	2	1	
Leukopenia			
subjects affected / exposed	3 / 18 (16.67%)	1 / 14 (7.14%)	
occurrences (all)	3	1	
Lymphopenia			
subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)	
occurrences (all)	0	1	
Neutropenia			
subjects affected / exposed	4 / 18 (22.22%)	2 / 14 (14.29%)	
occurrences (all)	4	2	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)	
occurrences (all)	0	0	
Abdominal pain upper			

subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)
occurrences (all)	1	0
Ascites		
subjects affected / exposed	0 / 18 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	1
Diarrhoea		
subjects affected / exposed	2 / 18 (11.11%)	2 / 14 (14.29%)
occurrences (all)	2	2
Dyspepsia		
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0
Haemorrhoids		
subjects affected / exposed	1 / 18 (5.56%)	1 / 14 (7.14%)
occurrences (all)	1	1
Nausea		
subjects affected / exposed	4 / 18 (22.22%)	2 / 14 (14.29%)
occurrences (all)	4	2
Vomiting		
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)
occurrences (all)	1	0
Abdominal distension		
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0
Anal pruritus		
subjects affected / exposed	2 / 18 (11.11%)	0 / 14 (0.00%)
occurrences (all)	2	0
Aphthous stomatitis		
subjects affected / exposed	0 / 18 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0
Constipation		
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)
occurrences (all)	1	0
Flatulence		
subjects affected / exposed	1 / 18 (5.56%)	0 / 14 (0.00%)
occurrences (all)	1	0
Proctalgia		

subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 14 (0.00%) 0	
Hepatobiliary disorders Liver tenderness subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)  Rash subjects affected / exposed occurrences (all)  Rash macular subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0  2 / 18 (11.11%) 2  0 / 18 (0.00%) 0	2 / 14 (14.29%) 2  1 / 14 (7.14%) 1  1 / 14 (7.14%) 2	
Renal and urinary disorders Haematuria subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Muscle tightness subjects affected / exposed occurrences (all)  Muscular weakness subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	1 / 14 (7.14%) 1  0 / 14 (0.00%) 0  1 / 14 (7.14%) 1	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)  Upper respiratory tract infection	1 / 18 (5.56%) 1	1 / 14 (7.14%) 1	

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Abscess limb subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Cellulitis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 14 (7.14%) 1	
Metabolism and nutrition disorders			
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 14 (7.14%) 1	
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 14 (0.00%) 0	
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 14 (0.00%) 0	

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported